711TiP A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors.
Saved in:
| Title: | 711TiP A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors. |
|---|---|
| Authors: | Weickhardt, A.J.1 (AUTHOR), Frentzas, S.2 (AUTHOR), Lemech, C.3 (AUTHOR), Srimani, J.4 (AUTHOR), Yin, J.5 (AUTHOR), Trepicchio, W.L.6 (AUTHOR), Gorgun, C.7 (AUTHOR), Kichenadasse, G.8 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS492-S492. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
